Oral PROTAC degrader for Bruton’s Tyrosine Kinase (BTK)
for hematological cancers and auto-immune disorders
Bruton’s tyrosine kinase (BTK) is a Tec family member of nonreceptor tyrosine kinase and plays an essential role for B cell maturation, activation, proliferation, differentiation, and maturation. BTK is implicated in pathogenesis of B-cell malignancies including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL) and Waldenstrom’s macroglobulinemia (WM). Therapies targeting BTK have proven their potential in both pre-clinical and clinical settings.
EnhancedBio is developing a novel BTK-Protac degrader with an orally bioavailable, small molecule, addressing the activity against proliferative diseases and autoimmune disorders, including hematological cancers and rheumatoid arthritis, particularly non-Hodgkin lymphoma; chronic lymphocytic leukemia (CLL) & mantle cell lymphoma.